|   News

The Revolution in Inflammation Drug Development


Chronic autoimmune and inflammatory diseases are painful and often lifelong conditions. I know this both as a scientist and a father, as my son, Jeremy, was diagnosed 12 years ago with Crohn’s disease, one type of inflammatory bowel disease (IBD). According to the National Institutes of Health, there are more than 80 autoimmune diseases affecting approximately 23.5 million Americans like Jeremy. Chronic inflammation related to other conditions such as non-alcoholic steatohepatitis (NASH), cardiovascular disease, and neurodegeneration including Alzheimer’s, could affect nearly 100 million others. Due to the clinical impact of inflammatory diseases and the shortcomings of existing therapies, now is the time to explore new pathways to treat patients.

Gary Glick is the CEO and co-founder of IFM Therapeutics, LLC, a Boston-based biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system for the treatment of inflammatory diseases.

Read more.